Palabras clave
Cómo citar
Resumen
Introducción: Las alteraciones del metabolismo óseo y mineral asociado a la enfermedad renal crónica (AMOM-ERC) es una de las complicaciones más frecuentes e importantes que afecta la calidad de vida de pacientes con enfermedad renal crónica y sus familias y, además, contribuye al aumento de la morbimortalidad cardiovascular.
Método: A partir de una revisión sistemática de literatura en las bases de datos Embase y Medline vía Pubmed, grupos desarrolladores de evidencia y sociedades científicas, se formularon recomendaciones preliminares por el grupo desarrollador que fueron consultadas a un colectivo experto de nefrología, endocrinología, geriatría, reumatología, medicina interna y cardiología, a través del método Delphi modificado.
Resultados: Se presentan 62 recomendaciones sobre diagnóstico y tratamiento de AMOM-ERC definidas por consenso entre 51 expertos clínicos y el grupo desarrollador. El rango de aprobación de las recomendaciones oscilo entre 80.9% y 100%.
Conclusión: Las recomendaciones presentadas permiten a los expertos clínicos la toma de decisiones clínicas cotidianas basadas en evidencia sobre el diagnóstico y el tratamiento de las alteraciones del metabolismo óseo y mineral en pacientes con enfermedad renal crónica en Colombia.
Citas
Schoolwerth AC, Engelgau MM, Hostetter TH. A public health action plan
is needed for chronic kidney disease. Adv Chronic Kidney Dis.
;12(4):418-23.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et
al. Global prevalence of chronic kidney disease - A systematic review and
meta-analysis. PLoS One. 2016;11(7):e0158765.
Ministerio de Salud y Protección Social; Ministerio de Hacienda y Crédito
Público. Cuenta de Alto Costo [Internet]. 2020 my. 30 [citado 2021 febr.
. Disponible en: https://cuentadealtocosto.org/site/quienes-somos/
Cuenta de Alto Costo Colombia. Situación de la Enfermedad Renal
Crónica, la Hipertensión Arterial y la Diabetes Mellitus en Colombia,
Cuenta Alto Costo [Internet]. 2019 [citado 2021 Feb 11];1(2322–
:293.
Disponible
en:
https://cuentadealtocosto.org/site/download/situacion-de-la-enfermedad-
renal-cronica-la-hipertension-arterial-y-diabetes-mellitus-en-colombia-
/
Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al.
The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344-58.
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et
al. Definition, evaluation, and classification of renal osteodystrophy: a
position statement from Kidney Disease: Improving Global Outcomes
(KDIGO). Kidney Int. 2006;69(11):1945-53.
Liabeuf S, McCullough K, Young EW, Pisoni R, Zee J, Reichel H, et al.
International variation in the management of mineral bone disorder in
patients with chronic kidney disease: Results from CKDopps. Bone.
;129:115058.
Luján MA, Ramírez JA, Acevedo JM, Gómez S, Cañas JM, Santander D,
et al. Prevalencia de las alteraciones del metabolismo óseo-mineral
asociadas a enfermedad renal crónica no en diálisis. Rev Colomb Nefrol
[Internet]. 2019 mzo 1;6(Artículo de investigación original):17-25.
Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/311
Nakai S, Watanabe Y, Masakane I, Wada A, Shoji T, Hasegawa T, et al.
Overview of regular dialysis treatment in Japan (as of 31 December
. Ther Apher Dial. 2013;17(6):567-611.
Colombia Compra Eficiente [sitio virtual]. Tratamiento de enfermedad
renal crónica. Bogotá: Colombia Compra Eficiente; 2020 [citado 2021
febr. 11]. Disponible en: https://www.colombiacompra.gov.co/tienda-
virtual-del-estado-colombiano/salud/tratamiento-de-enfermedad-renal-
cronica
The Economist. Value-based health in renal care in Latin America.
London:
The
Economist;
Disponible
en:
http://www.eiu.com/graphics/assets/images/public/VBH-in-Renal-Care-in-
Latin-America/Value-based-health-in-renal-care-in-Latin-America.pdf
Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs
AH. Economic evaluation of cinacalcet in the United States: The EVOLVE
Trial. Value Health. 2015;18(8):1079-87.
Liu ZH, Li G, Zhang L, Chen J, Chen X, Zhao J, et al. Executive
summary: Clinical practice guideline of chronic kidney disease - mineral
and
bone
disorder
(CKD-MBD)
in
China.
Kidney
Dis
(Basel).
;5(4):197-203.
Chen W, Bushinsky DA. Chronic kidney disease: KDIGO CKD–MBD
guideline update: evolution in the face of uncertainty. Nature Reviews
Nephrology. 2017;13(10):600-2.
Forbes A, Gallagher H. Chronic kidney disease in adults: Assessment
and
management.
Clinical
medicine
(Londres,
Inglaterra).
;20(2):128-32.
Malaysian Health Technology Assessment Section. Management of
Chronic
Kidney
Technology
Disease. Putrajaya,
Assessment Section;
Malasia:
Malaysian
Disponible
Health
en:
https://www.moh.gov.my/moh/resources/penerbitan/CPG/CPG
%20Management%20of%20Chronic%20Kidney%20%20Disease
%20(Second%20Edition).pdf
Ministerio de Salud Pública del Ecuador. Prevención, diagnóstico y
tratamiento de la enfermedad renal crónica. Guía de práctica clínica.
Quito: Ministerio de Salud Pública, Dirección Nacional de Normatización-
MSP;
Disponible
en:
https://www.salud.gob.ec/wp-content/uploads/2018/10/guia_prevencion_d
iagnostico_tratamiento_enfermedad_renal_cronica_2018.pdf
De Maré A, Verhulst A, Cavalier E, Delanaye P, Behets GJ, Meijers B, et
al. Clinical inference of serum and bone sclerostin levels in patients with
end-stage kidney disease. J Clin Med. 2019;8(12):2027.
Druck A, Patel D, Bansal V, Hoppensteadt D, Fareed J. Osteopontin
levels in patients with chronic kidney disease stage 5 on hemodialysis
directly
correlate
with
intact
parathyroid
hormone
and
alkaline
phosphatase. Clin Appl Thromb. 2019;25:1-5.
Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH,
Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone
histology in patients with CKD treated by dialysis. Am J Kidney Dis.
;67(4):559-66.
Aaltonen L, Koivuviita N, Seppänen M, Tong X, Kröger H, Löyttyniemi E,
et al. Correlation between 18F-Sodium Fluoride positron emission
tomography and bone histomorphometry in dialysis patients. Bone.
;134:115267.
Baptista AL, Padilha K, Malagrino PA, Venturini G, Zeri AC, Dos Reis LM,
et al. Potential biomarkers of the turnover, mineralization, and volume
classification: Results using NMR metabolomics in hemodialysis patients.
JBMR plus. 2020;4(7):e10372-e.
Aigner C, Cejka D, Sliber C, Fraunschiel M, Sunder-Plassmann G, Gaggl
M. Oral sodium bicarbonate supplementation does not affect serum
calcification propensity in patients with chronic kidney disease and
chronic metabolic acidosis. Kidney Blood Press Res. 2019;44(2):188-99.
Chen Z, Qureshi AR, Ripsweden J, Wennberg L, Heimburger O, Lindholm
B, et al. Vertebral bone density associates with coronary artery
calcification and is an independent predictor of poor outcome in end-stage
renal disease patients. Bone. 2016;92:50-7.
Liu Y, Lee WC, Cheng BC, Li LC, Lee CH, Chang WX, et al. Association
between the achievement of target range CKD-MBD markers and
mortality in prevalent hemodialysis patients in Taiwan by using the kidney
disease: Improving global outcomes clinical guidelines. Biomed Res Int.
;2016:1523124.
Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, et al.
KDIGO Clinical Practice Guideline on the Evaluation and Management of
Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1
Supl. 1):s11-s103.
Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan
W, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020
update. Am J Kidney Dis. 2020;76(3 Supl. 1):s1-s107.
Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The effect
of vitamin D supplementation on bone metabolic markers in chronic
kidney disease. J Bone Miner Res. 2018;33(3):404-9.
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al.
Phosphate binders for preventing and treating chronic kidney disease-
mineral and bone disorder (CKD-MBD). The Cochrane database of
systematic reviews. 2018;8(8):CD006023-CD.
Sekercioglu N, Thabane L, Díaz-Martínez JP, Nesrallah G, Longo CJ,
Busse JW, et al. Comparative effectiveness of phosphate binders in
patients with chronic kidney disease: A systematic review and network
meta-analysis. PLoS One. 2016;11(6):e0156891.
Sekercioglu N, Angeliki-Veroniki A, Thabane L, Busse JW, Akhtar-
Danesh N, Iorio A, et al. Effects of different phosphate lowering strategies
in patients with CKD on laboratory outcomes: A systematic review and
NMA. PLoS One. 2017;12(3):e0171028.
De Roij-Van Zuijdewijn CL, De Haseth DE, Van Dam B, Bax WA,
Grooteman MPC, Bots ML, et al. Role of albumin assay on calcium levels
and prescription of phosphate binders in chronic hemodialysis patients.
Nephron. 2018;140(3):211-7.
Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M,
Johansson S, Knutsson M, et al. Effect of tenapanor on serum phosphate
in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933-
Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of
tenapanor in patients with hyperphosphatemia receiving maintenance
hemodialysis: A randomized phase 3 Trial. J Am Soc Nephrol.
;30(4):641-52.
Malhotra R, Katz R, Hoofnagle A, Bostom A, Rifkin DE, McBride R, et al.
The effect of extended release niacin on markers of mineral metabolism
in CKD. Clin J Am Soc Nephrol. 2018;13(1):36-44.
Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes
LC, et al. Cinacalcet versus standard treatment for chronic kidney
disease:
a
systematic
review
and
meta-analysis.
Ren
Fail.
;38(6):857-74.
Ni LH, Yuan C, Song KY, Wang XC, Chen SJ, Wang LT, et al. Efficacy
and safety of cinacalcet and active vitamin D in the treatment of
secondary hyperparathyroidism in patients with chronic kidney disease: A
network meta-analysis. Ann Transl Med. 2019;7(14):322.
Greeviroj P, Kitrungphaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong
S, Jaber BL, et al. Cinacalcet for treatment of chronic kidney disease-
mineral and bone disorder: A meta-analysis of randomized controlled
trials. Nephron. 2018;139(3):197-210.
Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli
GFM. Comparative effectiveness of calcimimetic agents for secondary
hyperparathyroidism in adults: A systematic review and network meta-
analysis. Am J Kidney Dis. 2020;76(3):321-30.
Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of
cinacalcet on calcific uremic arteriolopathy events in patients receiving
hemodialysis:
The
EVOLVE
Trial.
Clin
J
Am
Soc
Nephrol.
;10(5):800-7.
Cozzolino M, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S.
Vitamin K in chronic kidney disease. Nutrients. 2019;11(1):168.
Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S,
Jaber BL, Susantitaphong P. Treatment of calciphylaxis in CKD:
A systematic review and meta-analysis. Kidney international reports.
;4(2):231-44.
Peng T, Zhuo L, Wang Y, Jun M, Li G, Wang L, et al. Systematic review
of sodium thiosulfate in treating calciphylaxis in chronic kidney disease
patients. Nephrology. 2018;23(7):669-75.
Coyne DW, Singh HN, Smith WT, Giuseppi AC, Connarn JN, Sherman
ML, et al. Sotatercept safety and effects on hemoglobin, bone, and
vascular calcification. Kidney Int Reports. 2019;4(11):1585-97.
Brandenburg VM, Sinha S, Torregrosa JV, Garg R, Miller S, Canals AZ,
et al. Improvement in wound healing, pain, and quality of life after 12
weeks of SNF472 treatment: a phase 2 open-label study of patients with
calciphylaxis. J Nephrol. 2019;32(5):811-21.
Ape trii M, Goldsmith D, Nistor I, Siriopol D, Voroneanu L, Scripcariu D, et
al. Impact of surgical parathyroidectomy on chronic kidney disease-
mineral and bone disorder (CKD-MBD) - A systematic review and meta-
analysis. PLoS One. 2017;12(11):e0187025.
Palmer SC, Chung EY, McGregor DO, Bachmann F, Strippoli GF.
Interventions for preventing bone disease in kidney transplant recipients.
The cochrane database of systematic reviews. 2019;10(10):CD005015-
CD.
Araujo M, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M, et
al. Persistent hyperparathyroidism as a risk factor for long-term graft
failure: the need to discuss indication for parathyroidectomy. Surgery.
;163(5):1144-50.
Nanmoku K, Shinzato T, Kubo T, Shimizu T, Takachi Y. Effects of
denosumab on hypercalcemia and bone mineral density loss in kidney
transplant recipients. Clin Nephrol. 2019;(0301-0430):1-9.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.